Literature DB >> 23092922

Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-κB.

Erin F Gillespie1, Nupur Raychaudhuri, Konstantinos I Papageorgiou, Stephen J Atkins, Ying Lu, Laya K Charara, Tünde Mester, Terry J Smith, Raymond S Douglas.   

Abstract

PURPOSE: CD40-CD40 ligand (CD40L) interactions appear to play pathogenic roles in autoimmune disease. Here we quantify CD40 expression on fibrocytes, circulating, and bone marrow-derived progenitor cells. The functional consequences of CD40 ligation are determined since these may promote tissue remodeling linked with thyroid-associated ophthalmopathy (TAO).
METHODS: CD40 levels on cultivated fibrocytes and orbital fibroblasts (GOFB) from patients with Graves' disease (GD), as well as fibrocyte abundance, were determined by flow cytometry. CD40 mRNA expression was evaluated by real-time PCR, whereas response to CD40 ligation was measured by Luminex and RT-PCR. Protein kinase B (Akt) and nuclear factor (NF)-kappa B (NF-κB) signaling were determined by Western blot and immunofluorescence.
RESULTS: Basal CD40 expression on fibrocytes is greater than that on GOFB. IFN-γ upregulates CD40 in both cell types and its actions are mediated at the pretranslational level. Fibrocytes produce high levels of cytokines, including interleukin-6 (IL-6), TNF-α, IL-8, MCP-1, and RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) in response to CD40L. IL-6 induction results from an increase in steady state IL-6 mRNA, and is mediated through Akt and NF-κB activation. Circulating CD40(+)CD45(+)Col1(+) fibrocytes are far more frequent in vivo in donors with TAO compared with healthy subjects.
CONCLUSIONS: Particularly high levels of functional CD40 are displayed by fibrocytes. CD40L-provoked signaling results in the production of several cytokines. Among these, IL-6 expression is mediated through Akt and NF-κB pathways. The frequency of circulating CD40(+) fibrocytes is markedly increased in patients with TAO, suggesting that this receptor might represent a therapeutic target for TAO.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23092922      PMCID: PMC3506052          DOI: 10.1167/iovs.12-9861

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  52 in total

Review 1.  Peripheral blood fibrocytes: mesenchymal precursor cells and the pathogenesis of fibrosis.

Authors:  J Chesney; R Bucala
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

2.  Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy.

Authors:  Terry J Smith; Laura Koumas; AnneMarie Gagnon; Andrea Bell; Gregory D Sempowski; Richard P Phipps; Alexander Sorisky
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

3.  Peripheral blood fibrocytes: differentiation pathway and migration to wound sites.

Authors:  R Abe; S C Donnelly; T Peng; R Bucala; C N Metz
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

Review 4.  Molecular mechanisms of CD40 signaling.

Authors:  G A Bishop; B S Hostager
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2001       Impact factor: 4.291

5.  CD40/CD40 ligand interactions are critical for elicitation of autoimmune-mediated fibrosis in the lung.

Authors:  J Zhang-Hoover; A Sutton; J Stein-Streilein
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

6.  Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production.

Authors:  Erin F Gillespie; Konstantinos I Papageorgiou; Roshini Fernando; Nupur Raychaudhuri; Kimberly P Cockerham; Laya K Charara; Allan C P Goncalves; Shuang-Xia Zhao; Anna Ginter; Ying Lu; Terry J Smith; Raymond S Douglas
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

7.  Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus.

Authors:  Christina G Katsiari; Stamatis-Nick C Liossis; Vassilis L Souliotis; Athanasios M Dimopoulos; Menelaos N Manoussakis; Petros P Sfikakis
Journal:  Clin Immunol       Date:  2002-04       Impact factor: 3.969

8.  Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy.

Authors:  Y Hiromatsu; D Yang; T Bednarczuk; I Miyake; K Nonaka; Y Inoue
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

Review 9.  IL-6 in autoimmune disease and chronic inflammatory proliferative disease.

Authors:  Katsuhiko Ishihara; Toshio Hirano
Journal:  Cytokine Growth Factor Rev       Date:  2002 Aug-Oct       Impact factor: 7.638

10.  The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance.

Authors:  Taishin Akiyama; Yusuke Shimo; Hiromi Yanai; Junwen Qin; Daisuke Ohshima; Yuya Maruyama; Yukiko Asaumi; Juli Kitazawa; Hiroshi Takayanagi; Josef M Penninger; Mitsuru Matsumoto; Takeshi Nitta; Yousuke Takahama; Jun-Ichiro Inoue
Journal:  Immunity       Date:  2008-09-19       Impact factor: 31.745

View more
  28 in total

Review 1.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

2.  CD40 Signaling in Graves Disease Is Mediated Through Canonical and Noncanonical Thyroidal Nuclear Factor κB Activation.

Authors:  Hanna J Lee; Angela Lombardi; Mihaela Stefan; Cheuk Wun Li; William B Inabnet; Randall P Owen; Erlinda Concepcion; Yaron Tomer
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

3.  PI3K/AKT pathway mediates induction of IL-1RA by TSH in fibrocytes: modulation by PTEN.

Authors:  Bin Li; Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2014-05-19       Impact factor: 5.958

Review 4.  Radiotherapy for Graves' disease. The possible role of low-dose radiotherapy.

Authors:  Meritxell Arenas; Sebastià Sabater; Pedro Lara Jiménez; Àngels Rovirosa; Albert Biete; Victoria Linares; Montse Belles; Julià Panés
Journal:  Rep Pract Oncol Radiother       Date:  2016-03-04

5.  Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside.

Authors:  Fatemeh Rajaii; Allison N McCoy; Terry J Smith
Journal:  Expert Rev Ophthalmol       Date:  2014-06

6.  Massive plasmacytosis with severe marrow suppression induced by methimazole in Graves' disease patients: case report and literature review.

Authors:  Feng Xiao; Chenying Li; Liangshun You; Wenbing Qian; Juying Wei
Journal:  Int J Clin Exp Med       Date:  2014-10-15

7.  Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis).

Authors:  Raymond S Douglas; Tünde Mester; Anna Ginter; Denise S Kim
Journal:  Trans Am Ophthalmol Soc       Date:  2014

Review 8.  Interleukin-6 blockade in ocular inflammatory diseases.

Authors:  M Mesquida; A Leszczynska; V Llorenç; A Adán
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

Review 9.  Potential Roles of CD34+ Fibrocytes Masquerading as Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

10.  Thyrotropin and CD40L Stimulate Interleukin-12 Expression in Fibrocytes: Implications for Pathogenesis of Thyroid-Associated Ophthalmopathy.

Authors:  Tong Wu; Tünde Mester; Shivani Gupta; Fengyuan Sun; Terry J Smith; Raymond S Douglas
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.